46.10
Alkermes Plc stock is traded at $46.10, with a volume of 1.05M.
It is down -1.66% in the last 24 hours and down -7.19% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$46.88
Open:
$46.14
24h Volume:
1.05M
Relative Volume:
0.55
Market Cap:
$7.73B
Revenue:
$1.56B
Net Income/Loss:
$152.72M
P/E Ratio:
51.26
EPS:
0.8994
Net Cash Flow:
$221.80M
1W Performance:
-2.76%
1M Performance:
-7.19%
6M Performance:
+57.45%
1Y Performance:
+59.41%
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
46.10 | 8.06B | 1.56B | 152.72M | 221.80M | 0.8994 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com India
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - news.stocktradersdaily.com
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - law360.com
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report? - Yahoo Finance
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive phase 2 trial results - Investing.com
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews
Alkermes (ALKS) Eases to $49.06: Key Levels to Watch After 0.79% DipPrice Target - Vinanet
S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat
Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat
Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat
Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView
Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media
Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria
Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada
Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView
Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan
Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com
Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance
Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st
The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat
Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat
(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):